Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Business Segments — Other Research and Development Expense

Similar metrics at other companies

Crinetics Pharmaceuticals logo
CRNXReportable Segment — Other Research and Development Expense
$8.3M+23.2%
Globus Medical logo
GMEDReportable Segment — Other Research and Development Expense
$10.19M+3.5%
Arvinas logo
ARVNReportable Segment — Other research and development expense
$2.4M-22.6%
Zymeworks logo
ZYMEReportable Segment — Other research and development expense
$4.66M-22.2%
Archer Aviation logo
ACHRReportable Segment — Other research and development expense
$136.9M+44.7%
Silicon Laboratories logo
SLABReportable Segment — Other research and development expenses
$56.28M+1.9%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.3B+320%
Enterprise value$1.32B+474%

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.

The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0002007919-26-000027
Line itemTHREE MONTHS ENDEDMARCH 31, 2026THREE MONTHS ENDEDMARCH 31, 2025
Personnel(8,527)(9,326)
Contract manufacturing(2,043)(8,550)
Equipment, depreciation, and facility(2,561)(2,583)
Other research and development(2,906)(3,153)
Total research and development expense(25,217)(36,877)
General and administrative expense
Personnel(3,646)(3,777)
Other general and administrative(2,064)(2,247)

Item 1. Financial Statements (unaudited)

FAQ

What is Inhibrx Biosciences, Inc.'s business segments — other research and development expense?
Inhibrx Biosciences, Inc. (INBX) reported business segments — other research and development expense of $2.91M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s business segments — other research and development expense changed year-over-year?
Inhibrx Biosciences, Inc.'s business segments — other research and development expense decreased by 7.8% year-over-year, from $3.15M to $2.91M.
What does business segments — other research and development expense mean?
This metric encompasses miscellaneous research and development costs not categorized under clinical trials, personnel, or manufacturing. It typically includes laboratory supplies, software licenses, and external consulting fees related to scientific research. It provides visibility into the ancillary costs necessary to support the broader R&D ecosystem.

Ask your AI about Inhibrx Biosciences, Inc.'s business segments — other research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude